AxoGen, Inc. (NASDAQ:AXGN) – Cantor Fitzgerald issued their FY2017 earnings per share estimates for shares of AxoGen in a research report issued on Sunday. Cantor Fitzgerald analyst C. Bijou forecasts that the medical equipment provider will post earnings per share of ($0.31) for the year. Cantor Fitzgerald currently has a “Buy” rating and a $37.00 target price on the stock. Cantor Fitzgerald also issued estimates for AxoGen’s FY2018 earnings at ($0.27) EPS.

AxoGen (NASDAQ:AXGN) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). AxoGen had a negative net margin of 24.74% and a negative return on equity of 91.00%. The business had revenue of $16.05 million during the quarter, compared to analysts’ expectations of $15.55 million. AxoGen’s quarterly revenue was up 43.2% on a year-over-year basis.

AXGN has been the subject of a number of other reports. Jefferies Group began coverage on shares of AxoGen in a research report on Thursday, November 30th. They set a “buy” rating and a $35.00 price target for the company. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Leerink Swann reissued an “outperform” rating and issued a $23.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Saturday, September 30th. Wedbush reissued a “buy” rating and issued a $27.00 price objective (up previously from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Finally, Lake Street Capital raised their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $29.33.

Shares of AxoGen (NASDAQ:AXGN) opened at $27.75 on Wednesday. AxoGen has a 12-month low of $8.75 and a 12-month high of $31.70. The firm has a market cap of $930.76, a PE ratio of -66.07 and a beta of 0.89. The company has a debt-to-equity ratio of 1.93, a quick ratio of 2.95 and a current ratio of 3.55.

Large investors have recently modified their holdings of the company. Neuberger Berman Group LLC purchased a new stake in shares of AxoGen during the 2nd quarter worth approximately $201,000. Valeo Financial Advisors LLC purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $244,000. OxFORD Asset Management LLP purchased a new stake in shares of AxoGen during the 3rd quarter worth approximately $270,000. Nationwide Fund Advisors lifted its position in shares of AxoGen by 5.5% during the 2nd quarter. Nationwide Fund Advisors now owns 14,874 shares of the medical equipment provider’s stock worth $249,000 after buying an additional 774 shares during the last quarter. Finally, Susquehanna International Group LLP lifted its position in shares of AxoGen by 247.1% during the 2nd quarter. Susquehanna International Group LLP now owns 16,619 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 27,919 shares during the last quarter. Institutional investors and hedge funds own 66.00% of the company’s stock.

In other news, Director Guido J. Neels sold 1,150,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $19.74, for a total transaction of $22,701,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jamie Mark Grooms sold 38,405 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $26.35, for a total transaction of $1,011,971.75. The disclosure for this sale can be found here. Insiders sold 1,293,990 shares of company stock valued at $26,494,898 in the last quarter. 9.33% of the stock is owned by insiders.

WARNING: “AxoGen, Inc. to Post FY2017 Earnings of ($0.31) Per Share, Cantor Fitzgerald Forecasts (AXGN)” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/01/12/axogen-inc-to-post-fy2017-earnings-of-0-31-per-share-cantor-fitzgerald-forecasts-axgn.html.

About AxoGen

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.